Abstract
The prolactin-inhibitor Bromocriptin was examined in an open study in comparison with Hexoestrol, a synthetic estrogen compound, in 31 patients with severe postpartal breast engorgement and in 38 patients with acute puerperal mastitis. In both indications a significantly faster clinical improvement was achieved with Bromocriptin. Also the incision-rate in cases of breast abscess was significantly lower in the Bromocriptin group. The inhibition of prolactin is considered the method of choice, as well in the prophylaxis as in the treatment of puerperal mastitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
